GlassScriptPhysician profile
Murthy S Vuppala
NPI 1093762346
$15,810.63
in general payments reported to CMS, 2019-2025
48 companies · $3,071 in 2025
The $3,071 reported for 2025 was more than what 83% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,334 · 2020: $1,372 · 2021: $1,969 · 2022: $2,526 · 2023: $2,234 · 2024: $2,305 · 2025: $3,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,569 · Education: $40.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,569.23 |
| Education | $40.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,986.26 | 2019-2025 | Airsupra, Breztri, Tezspire |
| Glaxosmithkline, LLC. | $2,843.89 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,237.16 | 2020-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,232.45 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Genzyme Corporation | $725.62 | 2019-2025 | |
| Insmed, INC. | $708.20 | 2020-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $604.13 | 2019-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $421.23 | 2019-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $420.27 | 2020-2025 | Glassia |
| Novo Nordisk INC | $413.79 | 2021-2025 | Wegovy |
| Amgen INC. | $368.37 | 2021-2025 | Tezspire |
| Harmony Biosciences LLC | $360.72 | 2020-2025 | Wakix |
| Genentech USA, INC. | $349.27 | 2019-2025 | Xolair |
| Merck Sharp & Dohme LLC | $241.89 | 2019-2025 | Zerbaxa |
| Actelion Pharmaceuticals US, INC. | $210.76 | 2019-2023 | Uptravi, Opsumit |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murthy Vuppala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.